DRU, Botswana registers Aurobindo Pharma's 9 ARV products at a time

Aurobindo Pharma Ltd has announced that DRU (Drugs regulatory unit) of Botswana has registered nine of its ARV products at a time. They are as follows:

Product: Lamivudine and Zidovudine tablet
Class: NRTI

Product: Zidovudine oral solution 50 mg / 5 ml
Class: NRTI

Product: Nevirapine Oral Suspension 50 mg / ml
Class: NNRTI

Product: Lamivudine oral solution 10 mg / ml
Class: NRTI

Product: Nevirapine 200 mg tablet
Class: NNRTI

Product: Stavudine 30 mg Capsules
Class: NRTI

Product: Stavudine 40 mg Capsules
Class: NRTI

Product: Lamivudine 150 mg tablets
Class: NRTI

Product: Lamivudine 300 mg tablets
Class: NRTI

The products are used extensively in the management of HIV positive patients. Botswana is a key market for ARVs and hence these registrations with the authorities would help the Company to consolidate its position in the said market.

Source : Equity Bulls

Keywords